BenevolentAI
financial highlights revenue drug discovery product technology a business operations bus underlying expenses related to share based payments other income operating loss revenue increase across collaboration with additional novel targets in chronic kidney disease and idiopathic pulmonary spend increase driven by advancing pipeline into later stages of development particularly ben adaptive phase i and ben ling enablement in net named programmes added into pipeline during the year in pence weighted average ordinary shares outstanding in millions spend increase increased expected to plateau bus spend driven predominantly by listing status and expected to maintain at this level | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
10 of 38
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Presentation
October 2022
financial highlights revenue increase across collaboration with a milestone reached related to the second novel target for idiopathic pulmonary spend increase driven by portfolio advancing into later stages of development in particular ben entering adaptive phase i clinical study spend increase increased which is set to plateau bus spend driven predominantly by listing status but expected to maintain at this level | BenevolentAI
Investor Day
September 2022
financial highlights revenue increase across collaboration with a milestone reached related to the second novel target for idiopathic pulmonary spend increase driven by portfolio advancing into later stages of development in particular ben entering adaptive phase i clinical study spend increase increased which is set to plateau bus spend driven predominantly by listing status but expected to maintain at this level | BenevolentAI
Related slides by other companies
Advantage Solutions
Results
March 2023
capitalization summary total debt of billion leverage at around net debt to adjusted no meaningful maturities for the next years debt capitalization equity capitalization as of | Advantage Solutions
Alkermes
Results
February 2023
appendix guidance to non adjustments | Alkermes
Entain Group
Results
March 2022
and net debt | Entain Group
Sonos
Results
February 2023
reconciliation of net income to adjusted | Sonos
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io